Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real‐life retrospective study
Neoadjuvant treatment with ipilimumab and nivolumab is effective in real-world patients with different melanoma subtypes, different stages of disease and even advanced primary tumor.
Authors
- Bernhard G. Weiss (ORCID: https://orcid.org/0000-0002-8368-0149)
- Lars E. French (ORCID: https://orcid.org/0000-0002-4629-1486)
- Lucie Heinzerling (ORCID: https://orcid.org/0000-0002-9074-8017)
- Frederick Klauschen (ORCID: https://orcid.org/0000-0002-9131-2389)
- Wulf Sienel
- Petra Zimmermann (ORCID: https://orcid.org/0000-0002-2388-4318)
- Wolfgang G. Kunz (ORCID: https://orcid.org/0000-0002-5021-1952)
- Dirk Tomsitz (ORCID: https://orcid.org/0000-0003-0036-072X)
- Teresa Kauke (ORCID: https://orcid.org/0000-0001-6569-9703)
- Jens Neumann (ORCID: https://orcid.org/0000-0001-9200-441X)
- Birte J. Siegmund
Institutions
- University of Miami (US)
- LMU Klinikum (DE)
- Universitätsklinikum Erlangen (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- JDDG Journal der Deutschen Dermatologischen Gesellschaft
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1111/ddg.15632
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09